Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-15T19:21:42.956Z Has data issue: false hasContentIssue false

Inflammatory and metabolic biomarkers of psychopathological dimensions of schizophrenia

Published online by Cambridge University Press:  23 March 2020

L. Gonzalez-Blanco*
Affiliation:
Servicio de Salud del Principado de Asturias, Psiquiatría, Oviedo, Spain Universidad de Oviedo, Área de Psiquiatría, Oviedo, Spain
M.P. García-Portilla
Affiliation:
Servicio de Salud del Principado de Asturias, Psiquiatría, Oviedo, Spain Universidad de Oviedo, Área de Psiquiatría, Oviedo, Spain Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Oviedo, Spain
L. Garcia-Alvarez
Affiliation:
Universidad de Oviedo, Área de Psiquiatría, Oviedo, Spain Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Oviedo, Spain
C. Iglesias
Affiliation:
Universidad de Oviedo, Área de Psiquiatría, Oviedo, Spain Servicio de Salud del Principado de Asturias, Psiquiatría, Langreo, Spain
P. Saiz
Affiliation:
Servicio de Salud del Principado de Asturias, Psiquiatría, Oviedo, Spain Universidad de Oviedo, Área de Psiquiatría, Oviedo, Spain Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Oviedo, Spain
A. Coto
Affiliation:
Universidad de Oviedo, Morfología y Biología Celular, Oviedo, Spain
J. Bobes
Affiliation:
Servicio de Salud del Principado de Asturias, Psiquiatría, Oviedo, Spain Universidad de Oviedo, Área de Psiquiatría, Oviedo, Spain Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Oviedo, Spain
*
*Corresponding author.

Abstract

Introduction

The concept of schizophrenia as a systemic disease includes, not only psychosis, but an increase in somatic comorbidity and cardiovascular risk [1]. Furthermore, it is known the implication of inflammation in the pathogenesis of schizophrenia [2].

Objectives

To determinate potential inflammatory/metabolic biomarkers of schizophrenia's dimensions.

Methods

Sample: 36 outpatients with schizophrenia for less than 11 years, under stable maintenance treatment (mean age [32.25], males [63.9%]) and their 36 matched controls (age [32.53 ± 6.63]; males [72.2%]).

Evaluation

PANSS, Clinical Assessment Interview for Negative Symptoms(CAINS), Calgary Scale(CDS), CGI, Personal and Social Performance Scale(PSP). Biomarkers: C-reactive protein (CRP), homocysteine, glucose, insulin, HOMA-IR (insulin resistance), cholesterol, HDL, LDL, triglycerides.

Results

Biomarkers differences between groups are shown in Table 1. Table 2 shows the correlations found after controlling for Body Mass Index [patients(28.61 ± 5.69);controls(24.64 ± 3.80);p = 0.001] and Smoking [patients(52.8%-yes);controls(5.6%-yes);p = 0.000].

Conclusions

1. CRP, a potential inflammatory biomarker in schizophrenia, is related to depression severity. Homocysteine, representing an oxidative stress, is related to positive, negative, cognitive and depressive symptoms severity, and worse functioning. 2. Patients with schizophrenia have lower HDL–related to negative and cognitive symptoms severity and worse functioning–and insulin resistance – related to worse cognition –.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EW517
Copyright
Copyright © European Psychiatric Association 2014

Table 1

Table 2

References

Kirkpatrick, B., Miller, B., García-Rizo, C., Fernandez-Egea, E. Schizophrenia: a systemic disorder. Clin Schizophr Relat Psychoses 8 2 2014 7379CrossRefGoogle ScholarPubMed
Miller, B.J., Buckley, P., et al.Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70 7 2011CrossRefGoogle ScholarPubMed
Figure 0

Table 1

Figure 1

Table 2

Submit a response

Comments

No Comments have been published for this article.